^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Enshuxing (enlonstobart)

    i
    Other names: SYSA 1802, SG001, SG 001, SYSA1802, SG-001, SYSA-1802
    Associations

    News

    Trials
    Company:
    CSPC Pharma, Sumgen Biotech
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=570, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    9d
    SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=396, Not yet recruiting, Shanghai Chest Hospital
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • ALK fusion • ROS1 fusion
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Enshuxing (enlonstobart)
    24d
    SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    29d
    SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=264, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P1/2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Enshuxing (enlonstobart)
    2ms
    Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1)
    |
    Enshuxing (enlonstobart)
    2ms
    A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=408, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2/3 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Enshuxing (enlonstobart)
    4ms
    Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (clinicaltrials.gov)
    P2, N=128, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Enshuxing (enlonstobart)
    5ms
    An open-label, multicenter, phase II study to evaluate the efficacy and safety of SYS6010 combined with enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma (ChiCTR2500112871)
    P2, N=70, Not yet recruiting, Shanghai East Hospital, Tongji University(Shanghai East Hospital); Shanghai East Hospital, Tongji University(Shanghai East Hospital)
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Enshuxing (enlonstobart) • SYS6010
    5ms
    Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR2500112440)
    P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • leucovorin calcium • Enshuxing (enlonstobart) • SYS6010
    5ms
    Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR2500112838)
    P1/2, N=622, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    cisplatin • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • pemetrexed • etoposide IV • Hetronifly (serplulimab) • Enshuxing (enlonstobart)
    5ms
    A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL) (ChiCTR2500111610)
    P1/2, N=43, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)
    5ms
    SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=70, Recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Enshuxing (enlonstobart) • SYS6010